HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wei, Y. Articles by Wagner, T. E. Search for Related Content PubMed PubMed Citation Articles by Wei, Y. Articles by Wagner, T. E.

Long-Term Expression of Human Growth Hormone (hGH) in Mice Containing Allogeneic Yolk Sac Cell Derived Neovascular Implants Expressing hGH

Edison Biotechnology Institute, Molecular and Cellular Biology Program and Department of Biological Science, Ohio University, Athens, Ohio, USA

Key Words. Yolk sac cell • Human growth hormone • Gene delivery • Gene therapy • Allogeneic mice • Rat-anti-mouse B7.2 antibody

Dr. Thomas E. Wagner, Edison Biotechnology Institute of Ohio University, Athens, OH 45701, USA.

We have established a systemic gene delivery animal model system by using cultured murine embryonic yolk sac cells, which can be easily genetically modified in vitro and participate in angiogenesis in vivo when basement membrane proteins (Matrigel) are provided in syngeneic mice. In the present study, we successfully applied this system to allogeneic mice. In order to suppress donor cell-specific immune responses, the costimulatory signal transduction pathway of T cell activation was blocked by treating the recipient allogeneic C57BL/6 mice with rat-antimouse B7.2 antibody. As a result of this suppression, human growth hormone, the therapeutic gene product, could be detected for over 340 days, while it could only be detected in mice treated with rat-IgG2a, the isotype control of anti-B7.2, for fewer than 50 days. This is the first ex vivo gene delivery system that can express a therapeutic gene product, long-term, in an allogeneic host.

This article has been cited by other articles:

				L. Pang, H.-H. Xue, G. Szalai, X. Wang, Y. Wang, D. K. Watson, W. J. Leonard, G. A. Blobel, and M. Poncz Maturation stage-specific regulation of megakaryopoiesis by pointed-domain Ets proteins Blood, October 1, 2006; 108(7): 2198 - 2206. [Abstract] [Full Text] [PDF]

				Y. Hazony, J. Lu, C. St. Hilaire, and K. Ravid Hematopoietic gene promoters subjected to a group-combinatorial study of DNA samples: identification of a megakaryocytic selective DNA signature Nucleic Acids Res., September 11, 2006; 34(16): 4416 - 4428. [Abstract] [Full Text] [PDF]

				K. Furihata and T. J. Kunicki Characterization of Human Glycoprotein VI Gene 5' Regulatory and Promoter Regions Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1733 - 1739. [Abstract] [Full Text] [PDF]

				I. C. Haznedaroglu, H. Goker, M. Turgut, Y. Buyukasik, and M. Benekli Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 193 - 212. [Abstract] [PDF]

				Y. Yamaguchi, L. I. Zon, S. J. Ackerman, M. Yamamoto, and T. Suda Forced GATA-1 Expression in the Murine Myeloid Cell Line M1: Induction of c-Mpl Expression and Megakaryocytic/Erythroid Differentiation Blood, January 15, 1998; 91(2): 450 - 457. [Abstract] [Full Text] [PDF]

				Y. Wei, J. Li, W. Y. Chen, and T. E. Wagner Human Growth Hormone Antagonist (G120R) Delivered by a Murine Yolk Sac Cell-Derived Mini-Organ Decreases the Growth Rate of Mice Stem Cells, September 1, 1997; 15(5): 364 - 367. [Abstract] [Full Text]